BACKGROUND: @entity5929 ( @entity5929 ) in @entity1577 ( @entity1577 ) is characterized by destructive changes in the airways. Long-term treatment with oral @entity288 is often required for repeated exacerbations. Because elevated total IgE is a cardinal abnormality of @entity5929 has been used sporadically to decrease @entity228 dose or totally replace @entity288 . OBJECTIVE: The aim of this report is to describe our experience with omalizumab treatment in @entity1 with @entity1577 and @entity5929 . METHODS: We conducted a review of 6 @entity1577 @entity1 with @entity5929 receiving omalizumab. All @entity1 were treated with oral @entity617 and @entity2059 . Omalizumab was started if the @entity1 was not responding to @entity479 treatment, which was determined according to serum IgE levels and/or clinical findings or depending on if there were side effects caused by @entity479 treatment. RESULTS: The mean age of @entity1 at the beginning of omalizumab treatment was 16.1 years. One @entity1 had a new diagnosis of @entity5929 ; however, the others had the first to third exacerbation when treated with omalizumab. The mean duration of @entity5929 by the time that treatment with omalizumab started was 13    12.4 months (range = 2-29 months). With omalizumab treatment, IgE levels were decreased in all @entity1 , and Aspergillus-specific IgE levels were decreased in 4 @entity1 ; however, FEV1(% predicted) improved only in 2 @entity1 who had mild disease. @entity288 were reduced in the first, second, and third months of omalizumab treatment in 2, 1, and 3 @entity1 , respectively. In 2 @entity1 , @entity479 treatment was stopped. None of the @entity1 suffered from side effects of omalizumab. The mean duration of omalizumab treatment was 12.5 months (range = 6-18 months). CONCLUSIONS: This study showed @entity479 -sparing effect, decreasing IgE levels, and improvement in respiratory symptoms in 6 @entity1577 @entity1 with omalizumab treatment. Although this is a small sample of the population, omalizumab may be an alternative therapy for @entity5929 in @entity1577 @entity1 who fail to respond to systemic @entity288 or have serious adverse effects.

Omalizumab Treatment for XXXX in @entity1577 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole'] @entity5929 :: ('MESH:D001229', 'Disease') :: ['ABPA, omalizumab', 'Allergic bronchopulmonary aspergillosis', 'ABPA'] @entity479 :: ('D013256', 'Chemical') :: ['steroid'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['CF', 'cystic fibrosis'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['Corticosteroids', 'corticosteroids']
@entity5929 :: (MESH:D001229,Disease) :: ['Allergic Bronchopulmonary Aspergillosis']
